GlassScriptPhysician profile
Mrunal Patil
NPI 1831323542
$1,475.58
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $114 · 2021: $407 · 2022: $327 · 2024: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $125.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $315.95 | 2019-2024 | Andexxa |
| Amgen INC. | $179.12 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $161.15 | 2019-2020 | |
| Novo Nordisk INC | $159.27 | 2021-2022 | |
| Glaxosmithkline, LLC. | $146.72 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.36 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $80.07 | 2019-2022 | |
| Pfizer INC. | $68.78 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $62.76 | 2021-2022 | |
| Lilly USA, LLC | $44.78 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.33 | 2021-2022 | |
| Edwards Lifesciences Corporation | $25.20 | 2024 | Sapien 3 Ultra Resilia |
| Allergan, INC. | $19.80 | 2019 | |
| Amarin Pharma, INC. | $18.47 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.44 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $18.29 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.84 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mrunal Patil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.